Ivonescimab

Akeso's Ivonescimab Wins ESMO Late-Breaking Slot for Biliary Cancer Data

Hong Kong – September 21, 2026 -- Akeso, Inc. (9926.HK) will present nearly 30 clinical studies of its bispecific antibodies at the European Society for Medical Oncology (ESMO) Congress in Madrid on October 23-27, 2026, including a Late-Breaking Abstract selected for the Presidential Symposium.

Phase III biliary tract cancer trial secures Presidential Symposium slot

Overall survival results from the Phase III HARMONi-GI1 trial, comparing ivonescimab plus chemotherapy against durvalumab plus chemotherapy as a first-line treatment for advanced biliary tract cancer, will be delivered as a late-breaking oral presentation (LBA8) on October 25 at 16:30-18:15 in Madrid. The presentation will be given by Jian Zhou of Shanghai during Presidential Symposium II.

China Inbound Medical Tourism Jumps 73.6% as Jiahui Cites WTO Forum

Geneva – September 20, 2026 -- China's leading hospitals serving international patients recorded 1.28 million international patient visits in 2025, up 73.6% from three years earlier, Dr. John K. Hsiang, Chairman of Jiahui Health's Executive Committee, said at the WTO Public Forum 2026.

Inbound patient volumes surge past 1.28 million visits in 2025

Of the 1.28 million total visits, 413,000 were made by patients who travelled to China specifically for medical care, according to data cited by Dr. Hsiang. At Jiahui Health, overseas patient inquiries nearly doubled year on year in the first half of 2026. Dr. Hsiang was the sole Chinese healthcare representative invited to the forum's "Health Without Borders" session on medical tourism in services trade.

Akeso's Ivonescimab Cuts Death Risk 27% vs Keytruda in NSCLC Trial

Hong Kong – September 16, 2026 -- Akeso, Inc. (9926.HK) reported that its bispecific antibody ivonescimab reduced the risk of death by 27% compared with Merck's pembrolizumab in a Phase III trial of PD-L1-positive non-small cell lung cancer (NSCLC), with results presented as a Late-Breaking Abstract at the 2026 World Conference on Lung Cancer (WCLC).

Ivonescimab extends median survival to 30.8 months in head-to-head trial

In the intention-to-treat population of the HARMONi-2 study (AK112-303), patients treated with ivonescimab monotherapy achieved a median overall survival (OS) of 30.8 months versus 22.6 months for pembrolizumab (HR=0.73; 95% CI: 0.57–0.95; P=0.009). The data cutoff was August 20, 2026, with a median follow-up of 36 months and 234 OS events recorded. Professor Caicun Zhou, principal investigator and IASLC President, is scheduled to deliver the full oral presentation on September 15.

Akeso's Ivonescimab Beats Pembrolizumab on Survival in Phase III NSCLC Trial

Hong Kong – September 07, 2026 -- Akeso, Inc. (9926.HK) said its bispecific antibody ivonescimab produced a statistically significant and clinically meaningful overall survival benefit versus Merck's pembrolizumab in a pre-specified interim analysis of the Phase III HARMONi-2 trial, as assessed by an Independent Data Monitoring Committee.

Ivonescimab clears key secondary survival endpoint against Keytruda

The HARMONi-2 (AK112-303) study is a randomized, double-blind, multicenter registrational trial testing ivonescimab against pembrolizumab as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 at a TPS of 1% or higher. Detailed interim overall survival data will be presented at an upcoming international medical conference and published in a peer-reviewed journal.